

**Table 1.** Maximum-likelihood parameter estimates for the plesiotypic 3FTX from ‘non-front-fanged’ advanced snakes

Model	Likelihood (l)	$\omega_0^a$	Parameters	Sign. <sup>b</sup>	No. of Sites with $\omega > 1^c$	B.E.B
M0 (One ratio)	-3678.383646	1.29	$= \omega_0$			-
M1 (Neutral)	-3585.956425	0.72	P <sub>0</sub> : 0.314 $\omega_0$ : 0.126 P <sub>1</sub> : 0.685 $\omega_1$ : 1.0			-
M2 (Selection)*	-3540.037278	1.71	P <sub>0</sub> : 0.218 $\omega_0$ : 0.13 P <sub>1</sub> : 0.328 $\omega_1$ : 1.0 P <sub>2</sub> : 0.452 $\omega_2$ : 3.0 P <sub>0</sub> : 0.206 $\omega_0$ : 0.11 P <sub>1</sub> : 0.330 $\omega_1$ : 0.91 P <sub>2</sub> : 0.462 $\omega_2$ : 2.91	P << 0.001	18 (PP $\geq$ 0.99) 8 (P $\geq$ 0.95)	
M3 (Discrete)*	-3539.925471	1.67	p: 0.34252 q: 0.13966 p <sub>0</sub> : 0.534 p: 0.447 q: 0.316 p <sub>1</sub> : 0.465 $\omega$ : 2.84	P << 0.001		-
M7 (beta)	-3588.471551	0.71				-
M8 (beta and $\omega$ )*	-3539.994764	1.63		P << 0.001	27 (PP $\geq$ 0.99) 10 (P $\geq$ 0.95)	

**Legend:**

**a:** dn/ds (weighted average)

**b:** Significance of the model in comparison with the null model

**c:** Number of sites with  $\omega > 1$  under the Bayes empirical Bayes approach with a posterior probability (PP) more than or equal to 0.99 and 0.95

\* Models which allow  $\omega > 1$

**Table 2.** Maximum-likelihood parameter estimates for the plesiotypic 3FTX from Viperidae

Model	Likelihood (l)	$\omega_0^a$	Parameters	Sign. <sup>b</sup>	No. of Sites with $\omega > 1^c$
<b>B.E.B</b>					
<b>M0 (One ratio)</b>	-1195.940485	1.79	= $\omega_0$		-
<b>M1 (Neutral)</b>	-1178.683529	0.67	P <sub>0</sub> : 0.344 $\omega_0$ : 0.05 P <sub>1</sub> : 0.655 $\omega_1$ : 1.0		-
<b>M2 (Selection)*</b>	-1155.587491	3.28	P <sub>0</sub> : 0.454 $\omega_0$ : 0.37 P <sub>1</sub> : 0.0 $\omega_1$ : 1.0 P <sub>2</sub> : 0.545 $\omega_2$ : 5.70 P <sub>0</sub> : 0.427 $\omega_0$ : 0.33 P <sub>1</sub> : 0.485 $\omega_1$ : 4.86 P <sub>2</sub> : 0.086 $\omega_2$ : 16.4	P << 0.001	13 (PP $\geq$ 0.99) 11 (P $\geq$ 0.95)
<b>M3 (Discrete)*</b>	-1153.672936	3.93	p: 0.03813 q: 0.01410 p <sub>0</sub> : 0.454 p: 58.52 q: 99.0 p <sub>1</sub> : 0.545 $\omega$ : 5.71	P << 0.001	-
<b>M7 (beta)</b>	-1179.346712	0.71			-
<b>M8 (beta and <math>\omega</math>)*</b>	-1155.588330	3.28		P << 0.001	18 (PP $\geq$ 0.99) 12 (P > 0.95)

**Legend:****a:** dn/ds (weighted average)**b:** Significance of the model in comparison with the null model**c:** Number of sites with  $\omega > 1$  under the Bayes empirical Bayes approach with a posterior probability (PP) more than or equal to 0.99 and 0.95\* Models which allow  $\omega > 1$

**Table 3.** Maximum-likelihood parameter estimates for the plesiotypic 3FTX from Elapidae

Model	Likelihood (l)	$\omega_0^a$	Parameters	Sign. <sup>b</sup>	No. of Sites with $\omega > 1^c$
<b>B.E.B</b>					
<b>M0 (One ratio)</b>	-1885.178988	1.30	$= \omega_0$		-
<b>M1 (Neutral)</b>	-1833.771080	0.60	P <sub>0</sub> : 0.419 $\omega_0$ : 0.05 P <sub>1</sub> : 0.580 $\omega_1$ : 1.0		-
<b>M2 (Selection)*</b>	-1807.546142	1.79	P <sub>0</sub> : 0.355 $\omega_0$ : 0.08 P <sub>1</sub> : 0.249 $\omega_1$ : 1.0 P <sub>2</sub> : 0.395 $\omega_2$ : 3.83 P <sub>0</sub> : 0.313 $\omega_0$ : 0.24 P <sub>1</sub> : 0.279 $\omega_1$ : 0.81 P <sub>2</sub> : 0.407 $\omega_2$ : 3.70	P << 0.001	15 (PP $\geq$ 0.99) 9 (P $\geq$ 0.95)
<b>M3 (Discrete)*</b>	-1807.476797	1.75	p: 0.03086 q: 0.01787 p <sub>0</sub> : 0.594 p: 0.236 q: 0.325 p <sub>1</sub> : 0.405 $\omega$ : 3.72	P << 0.001	-
<b>M7 (beta)</b>	-1835.536623	0.61			-
<b>M8 (beta and <math>\omega</math>)*</b>	-1807.523245	1.75		P << 0.001	22 (PP $\geq$ 0.99) 6 (P > 0.95)

**Legend:****a:** dn/ds (weighted average)**b:** Significance of the model in comparison with the null model**c:** Number of sites with  $\omega > 1$  under the Bayes empirical Bayes approach with a posterior probability (PP) more than or equal to 0.99 and 0.95\* Models which allow  $\omega > 1$

**Table 4.** Maximum-likelihood parameter estimates for type I (short-chain)  $\alpha$ -neurotoxins

Model	Likelihood (l)	$\omega_0^a$	Parameters	Sign. <sup>b</sup>	No. of Sites with $\omega > 1^c$	B.E.B
M0 (One ratio)	-3446.886907	1.92	$= \omega_0$			-
M1 (Neutral)	-3372.647732	0.57	P <sub>0</sub> : 0.485 $\omega_0$ : 0.12 P <sub>1</sub> : 0.514 $\omega_1$ : 1.0			-
M2 (Selection)*	-3285.128559	1.61	P <sub>0</sub> : 0.349 $\omega_0$ : 0.16 P <sub>1</sub> : 0.369 $\omega_1$ : 1.0 P <sub>2</sub> : 0.280 $\omega_2$ : 4.24 P <sub>0</sub> : 0.487 $\omega_0$ : 0.33 P <sub>1</sub> : 0.410 $\omega_1$ : 2.67 P <sub>2</sub> : 0.102 $\omega_2$ : 8.86	P << 0.001	11 (PP $\geq$ 0.99) 2 (P > 0.95)	
M3 (Discrete)*	-3264.912926	2.16	p:0.28637 q:0.21125 p <sub>0</sub> : 0.703 p: 0.303 q: 0.193 p <sub>1</sub> : 0.296 $\omega$ : 4.35	P << 0.001		-
M7 (beta)	-3380.125103	0.57				-
M8 (beta and $\omega$ )*	-3287.175727	1.72		P << 0.001	13 (PP $\geq$ 0.99) 6 (P > 0.95)	

**Legend:****a:** dn/ds (weighted average)**b:** Significance of the model in comparison with the null model**c:** Number of sites with  $\omega > 1$  under the Bayes empirical Bayes approach with a posterior probability (PP) more than or equal to 0.99 and 0.95\* Models which allow  $\omega > 1$

**Table 5.** Maximum-likelihood parameter estimates for type II (long-chain)  $\alpha$ -neurotoxins

Model	Likelihood (l)	$\omega_0^a$	Parameters	Sign. <sup>b</sup>	No. of Sites with $\omega > 1^c$
					B.E.B
<b>M0 (One ratio)</b>	-7338.701541	2.01	$= \omega_0$		-
<b>M1 (Neutral)</b>	-7080.814722	0.62	P <sub>0</sub> : 0.405 $\omega_0$ : 0.06 P <sub>1</sub> : 0.594 $\omega_1$ : 1.0		-
<b>M2 (Selection)*</b>	-6845.160604	1.43	P <sub>0</sub> : 0.384 $\omega_0$ : 0.10 P <sub>1</sub> : 0.356 $\omega_1$ : 1.0 P <sub>2</sub> : 0.259 $\omega_2$ : 4.008 P <sub>0</sub> : 0.402 $\omega_0$ : 0.18 P <sub>1</sub> : 0.461 $\omega_1$ : 2.54 P <sub>2</sub> : 0.136 $\omega_2$ : 8.28	P << 0.001	17 (PP $\geq$ 0.99) 2 (P > 0.95)
<b>M3 (Discrete)*</b>	-6801.590700	2.37	p: 0.18047 q: 0.16001 p <sub>0</sub> : 0.736 p: 0.210 q: 0.168 p <sub>1</sub> : 0.263 $\omega$ : 3.97	P << 0.001	-
<b>M7 (beta)</b>	-7078.743858	0.53			-
<b>M8 (beta and <math>\omega</math>)*</b>	-6853.164183	1.45		P << 0.001	19 (PP $\geq$ 0.99) 2 (P > 0.95)

**Legend:****a:** dn/ds (weighted average)**b:** Significance of the model in comparison with the null model**c:** Number of sites with  $\omega > 1$  under the Bayes empirical Bayes approach with a posterior probability (PP) more than or equal to 0.99 and 0.95\* Models which allow  $\omega > 1$

**Table 6.** Maximum-likelihood parameter estimates for type III  $\alpha$ -neurotoxins

Model	Likelihood (l)	$\omega_0^a$	Parameters	Sign. <sup>b</sup>	No. of Sites with $\omega > 1^c$
<b>B.E.B</b>					
<b>M0 (One ratio)</b>	-3312.727326	2.59	$= \omega_0$		-
<b>M1 (Neutral)</b>	-3210.492742	0.58	$P_0: 0.428$ $\omega_0: 0.04$ $P_1: 0.571$ $\omega_1: 1.0$		-
<b>M2 (Selection)*</b>	-3089.176251	2.59	$P_0: 0.333$ $\omega_0: 0.03$ $P_1: 0.247$ $\omega_1: 1.0$ $P_2: 0.418$ $\omega_2: 5.57$ $P_0: 0.413$ $\omega_0: 0.12$ $P_1: 0.272$ $\omega_1: 2.58$ $P_2: 0.314$ $\omega_2: 8.0$	$P << 0.001$	26 (PP $\geq 0.99$ ) 1 (P $> 0.95$ )
<b>M3 (Discrete)*</b>	-3079.356207	3.27	$p: 0.01764$ $q: 0.02272$ $p_0: 0.577$ $p: 0.019$ $q: 0.025$ $p_1: 0.422$ $\omega: 5.61$	$P << 0.001$	-
<b>M7 (beta)</b>	-3215.119806	0.42			-
<b>M8 (beta and <math>\omega</math>)*</b>	-3089.367982	2.61		$P << 0.001$	26 (PP $\geq 0.99$ ) 4 (P $> 0.95$ )

**Legend:****a:** dn/ds (weighted average)**b:** Significance of the model in comparison with the null model**c:** Number of sites with  $\omega > 1$  under the Bayes empirical Bayes approach with a posterior probability (PP) more than or equal to 0.99 and 0.95\* Models which allow  $\omega > 1$

**Table 7.** Maximum-likelihood parameter estimates for *Oxyuranus* / *Pseudonaja* Type II (long-chain)  $\alpha$ -neurotoxin with cysteine doublet

Model	Likelihood (l)	$\omega_0^a$	Parameters	Sign. <sup>b</sup>	No. of Sites with $\omega > 1^c$
<b>B.E.B</b>					
<b>M0 (One ratio)</b>	-953.657356	0.97	$= \omega_0$		-
<b>M1 (Neutral)</b>	-943.204575	0.62	P <sub>0</sub> : 0.375 $\omega_0$ : 0.0 P <sub>1</sub> : 0.624 $\omega_1$ : 1.0		-
<b>M2 (Selection)*</b>	-918.331297	3.57	P <sub>0</sub> : 0.157 $\omega_0$ : 0.0 P <sub>1</sub> : 0.529 $\omega_1$ : 1.0 P <sub>2</sub> : 0.312 $\omega_2$ : 9.75 P <sub>0</sub> : 0.625 $\omega_0$ : 0.62 P <sub>1</sub> : 0.341 $\omega_1$ : 8.51 P <sub>2</sub> : 0.032 $\omega_2$ : 47.15	P << 0.001	10 (PP $\geq$ 0.99) 7 (P > 0.95)
<b>M3 (Discrete)*</b>	-916.570131	4.82	p: 0.00754 q: 0.00500 p <sub>0</sub> : 0.674 p: 17.55 q: 6.79 p <sub>1</sub> : 0.325 $\omega$ : 9.77	P << 0.001	-
<b>M7 (beta)</b>	-943.258977	0.60			-
<b>M8 (beta and <math>\omega</math>)*</b>	-918.427424	3.67		P << 0.001	11 (PP $\geq$ 0.99) 7 (P > 0.95)

**Legend:**

**a:** dn/ds (weighted average)

**b:** Significance of the model in comparison with the null model

**c:** Number of sites with  $\omega > 1$  under the Bayes empirical Bayes approach with a posterior probability (PP) more than or equal to 0.99 and 0.95

\* Models which allow  $\omega > 1$

**Table 8.** Maximum-likelihood parameter estimates for *Oxyuranus* / *Pseudonaja* Type II (long-chain)  $\alpha$ -neurotoxin without cysteine doublet

Model	Likelihood (l)	$\omega_0^a$	Parameters	Sign. <sup>b</sup>	No. of Sites with $\omega > 1^c$
<b>B.E.B</b>					
<b>M0 (One ratio)</b>	-843.272386	2.69	$= \omega_0$		-
<b>M1 (Neutral)</b>	-845.722868	0.76	P <sub>0</sub> : 0.237 $\omega_0$ : 0.0 P <sub>1</sub> : 0.762 $\omega_1$ : 1.0		-
<b>M2 (Selection)*</b>	-832.929158	3.41	P <sub>0</sub> : 0.416 $\omega_0$ : 0.06 P <sub>1</sub> : 0.0 $\omega_1$ : 1.0 P <sub>2</sub> : 0.583 $\omega_2$ : 5.80	P << 0.001	2 (PP $\geq$ 0.99) 12 (P > 0.95)
<b>M3 (Discrete)*</b>	-832.929158	3.41	P <sub>0</sub> : 0.416 $\omega_0$ : 0.06 P <sub>1</sub> : 0.476 $\omega_1$ : 5.80 P <sub>2</sub> : 0.107 $\omega_2$ : 5.80	P << 0.001	-
<b>M7 (beta)</b>	-846.563004	0.90	p: 0.04683 q: 0.00500 p <sub>0</sub> : 0.416 p: 6.49		-
<b>M8 (beta and <math>\omega</math>)*</b>	-832.929285	3.41	q: 98.96 p <sub>1</sub> : 0.583 $\omega$ : 5.80	P << 0.001	9 (PP $\geq$ 0.99) 11 (P > 0.95)

**Legend:**

**a:** dn/ds (weighted average)

**b:** Significance of the model in comparison with the null model

**c:** Number of sites with  $\omega > 1$  under the Bayes empirical Bayes approach with a posterior probability (PP) more than or equal to 0.99 and 0.95

\* Models which allow  $\omega > 1$



**Table 9.** Maximum-likelihood parameter estimates for kappa three-finger toxins

Model	Likelihood (l)	$\omega_0^a$	Parameters	Sign. <sup>b</sup>	No. of Sites with $\omega > 1^c$
<b>B.E.B</b>					
<b>M0 (One ratio)</b>	-745.132731	1.64	$= \omega_0$		-
<b>M1 (Neutral)</b>	-743.698028	0.66	$P_0: 0.344$ $\omega_0: 0.03$ $P_1: 0.655$ $\omega_1: 1.0$		-
<b>M2 (Selection)*</b>	-728.968534	2.11	$P_0: 0.782$ $\omega_0: 1.0$ $P_1: 0.124$ $\omega_1: 1.0$ $P_2: 0.09$ $\omega_2: 12.96$ $P_0: 0.871$ $\omega_0: 0.95$	$P << 0.001$	3 ( $PP \geq 0.99$ ) 2 ( $P > 0.95$ )
<b>M3 (Discrete)*</b>	-728.457588	2.30	$P_1: 0.1$ $\omega_1: 7.61$ $P_2: 0.2$ $\omega_2: 25.61$	$P << 0.001$	-
<b>M7 (beta)</b>	-743.727286	0.70	$p: 0.01191$ $q: 0.00500$ $p_0: 0.906$ $p: 3.212$		-
<b>M8 (beta and <math>\omega</math>)*</b>	-728.968534	2.11	$q: 0.005$ $p_1: 0.093$ $\omega: 12.96$	$P << 0.001$	3 ( $PP \geq 0.99$ ) 2 ( $P > 0.95$ )

**Legend:****a:** dn/ds (weighted average)**b:** Significance of the model in comparison with the null model**c:** Number of sites with  $\omega > 1$  under the Bayes empirical Bayes approach with a posterior probability (PP) more than or equal to 0.99 and 0.95\* Models which allow  $\omega > 1$

**Table 10.** Maximum-likelihood parameter estimates for cytotoxic three-finger toxins

Model	Likelihood (l)	$\omega_0^a$	Parameters	Sign. <sup>b</sup>	No. of Sites with $\omega > 1^c$
<b>B.E.B</b>					
<b>M0 (One ratio)</b>	-970.316160	0.32	$= \omega_0$		-
<b>M1 (Neutral)</b>	-952.107186	0.33	P <sub>0</sub> : 0.712 $\omega_0$ : 0.06 P <sub>1</sub> : 0.287 $\omega_1$ : 1.0		-
<b>M2 (Selection)*</b>	-945.995693	0.57	P <sub>0</sub> : 0.675 $\omega_0$ : 0.06 P <sub>1</sub> : 0.294 $\omega_1$ : 1.0 P <sub>2</sub> : 0.029 $\omega_2$ : 8.18 P <sub>0</sub> : 0.518 $\omega_0$ : 0.0 P <sub>1</sub> : 0.446 $\omega_1$ : 0.62 P <sub>2</sub> : 0.034 $\omega_2$ : 7.02	P << 0.001	1 (PP $\geq$ 0.99) 1 (P $\geq$ 0.95)
<b>M3 (Discrete)*</b>	-945.501674	0.52	p: 0.13885 q: 0.29569 p <sub>0</sub> : 0.969 p: 0.173 q: 0.387 p <sub>1</sub> : 0.03 $\omega$ : 7.53	P < 0.01	-
<b>M7 (beta)</b>	-952.219533	0.31			-
<b>M8 (beta and <math>\omega</math>)*</b>	-945.530089	0.53		P < 0.01	2 (PP $\geq$ 0.99) 0 (P > 0.95)

**Legend:****a:** dn/ds (weighted average)**b:** Significance of the model in comparison with the null model**c:** Number of sites with  $\omega > 1$  under the Bayes empirical Bayes approach with a posterior probability (PP) more than or equal to 0.99 and 0.95\* Models which allow  $\omega > 1$ **p > 0.05<sup>N.S.</sup>:** Not significant at 0.05

**Supplementary Table 11.** Nucleotide and complementary amino acid-level selection assessment

Site		CodeML		TreeSAAP		ASA
Codon	AA	M2a <sup>a</sup>	M8 <sup>b</sup>	Property <sup>c</sup>	Magnitude <sup>d</sup>	
Type I $\alpha$ neurotoxins						
22	M	4.428±0.412 (0.989)*	4.456±0.247 (0.998)**	—	—	35.5 NA
37	M	4.466±0.209 (1.0)**	4.461±0.201 (1.0)**	$\alpha c$	6	39.9 Part. Exposed
39	A	4.444±0.341 (0.994)**	4.456±0.243 (0.999)**	$\alpha c$	6	95.5 Exposed
40	-	4.290±0.783 (0.950)	4.407±0.479 (0.985)*	$\alpha c$	6	100 Exposed
43	S	4.274±0.813 (0.945)	4.424±0.411 (0.990)*	<i>Hnc</i> , $\alpha c$	7, 6	69.5 Exposed
49	T	4.466±0.208 (1.0)**	4.461±0.201 (1.0)**	<i>Hnc</i> , $\alpha c$	7, 6	66.4 Exposed
51	R	4.466±0.208 (1.0)**	4.461±0.201 (1.0)**	<i>Hnc</i> , $R_{\alpha}$	8, 6	96.4 Exposed
53	H	4.466±0.210 (1.0)**	4.461±0.202 (1.0)**	<i>Hnc</i> , $R_{\alpha}$	8, 6	90.2 Exposed
56	T	4.224±0.900 (0.931)	4.403±0.493 (0.984)*	<i>Hnc</i> , $\alpha c$ , $R_{\alpha}$	8, 8, 6	77.9 Exposed
57	I	4.428±0.414 (0.989)*	4.455±0.253 (0.998)**	<i>Hnc</i> , $\alpha c$ , $R_{\alpha}$	8, 8, 6	72.6 Exposed
58	I	4.147±1.014 (0.909)	4.392±0.527 (0.981)*	<i>Hnc</i> , $\alpha c$ , $R_{\alpha}$	8, 8, 6	8.7 Buried
66	K	4.466±0.208 (1.0)**	4.461±0.201 (1.0)**	<i>Hnc</i> , $\alpha c$ , $R_{\alpha}$	8, 6, 6	40.5 Part. Exposed
69	P	4.466±0.208 (1.0)**	4.461±0.201 (1.0)**	<i>Hnc</i> , $\alpha c$ , $R_{\alpha}$	8, 6, 6	99.7 Exposed
70	G	4.455±0.283 (0.997)**	4.459±0.219 (0.999)**	<i>Hnc</i> , $\alpha c$ , $R_{\alpha}$	8, 7, 6	98 Exposed
71	I	3.812±1.360 (0.814)	4.289±0.782 (0.952)*	$\alpha c$	7	23.5 NA
72	K	4.466±0.208 (1.0)**	4.461±0.201 (1.0)**	$\alpha c$	7	65.9 Exposed
73	L	3.990±1.202 (0.864)	4.310±0.741 (0.958)*	$\alpha c$	7	14.2 Buried
74	E	4.466±0.208 (1.0)**	4.461±0.201 (1.0)**	<i>Hnc</i> , $\alpha c$	7, 7	69.8 Exposed
77	K	4.466±0.208 (1.0)**	4.461±0.201 (1.0)**	<i>Hnc</i> , $\alpha c$	7, 7	41.3 Part. Exposed
Type II $\alpha$ neurotoxins						
22	L	4.248±0.434 (1.0)**	3.612±0.649 (0.965)*	<i>b</i>	6	17.7 Buried

Site		CodeML		TreeSAAP		ASA
26	M	4.248±0.434 (1.0)**	3.735±0.424 (1.0)**	<i>b</i>	6	0 Buried
29	P	4.248±0.434 (1.0)**	3.735±0.424 (1.0)**	<i>b</i>	6	100 Exposed
30	K	4.235±0.477 (0.996)**	3.733±0.428 (1.0)**	<i>b</i>	6	46 Part. Exposed
31	T	4.248±0.434 (1.0)**	3.735±0.424 (1.0)**	<i>b</i>	6	38.3 NA
33	R	4.248±0.434 (1.0)**	3.735±0.424 (1.0)**	<i>b</i>	6	45.7 Part. Exposed
39	E	4.217±0.529 (0.991)**	3.730±0.434 (0.999)**	<i>pK<sup>1</sup>, b</i>	7, 6	62.4 Exposed
40	N	4.247±0.436 (1.0)**	3.735±0.424 (1.0)**	<i>pK<sup>1</sup>, b</i>	7, 6	70.4 Exposed
41	L	4.245±0.445 (0.999)**	3.734±0.426 (1.0)**	<i>pK<sup>1</sup>, b</i>	7, 6	18.4 Buried
50	P	4.248±0.434 (1.0)**	3.735±0.424 (1.0)**	<i>pK<sup>1</sup>, b</i>	8, 8	57.7 Exposed
51	R	4.248±0.434 (1.0)**	3.735±0.424 (1.0)**	<i>pK<sup>1</sup>, b</i>	8, 8	50.9 Exposed
53	S	4.248±0.434 (1.0)**	3.735±0.424 (1.0)**	<i>pK<sup>1</sup>, b</i>	8, 8	56.7 Exposed
54	S	4.248±0.434 (1.0)**	3.735±0.424 (1.0)**	<i>pK<sup>1</sup>, b</i>	8, 8	80.2 Exposed
58	L	4.248±0.434 (1.0)**	3.735±0.424 (1.0)**	<i>pK<sup>1</sup>, b</i>	7, 8	41.8 Part. Exposed
69	I	4.248±0.434 (1.0)**	3.735±0.424 (1.0)**	<i>pK<sup>1</sup>, b</i>	7, 6	84.6 Exposed
70	P	4.248±0.434 (1.0)**	3.735±0.424 (1.0)**	<i>pK<sup>1</sup>, b</i>	8, 6	—
72	S	4.200±0.575 (0.986)*	3.726±0.445 (0.997)**	<i>pK<sup>1</sup></i>	8	100 Exposed
73	Y	3.548±1.343 (0.799)	3.613±0.650 (0.964)**	<i>pK<sup>1</sup></i>	8	75.4 Exposed
74	E	4.145±0.698 (0.971)*	3.719±0.460 (0.996)**	<i>pK<sup>1</sup></i>	8	23.8 NA
75	D	4.248±0.435 (1.0)**	3.735±0.424 (1.0)**	<i>pK<sup>1</sup></i>	8	61.4 Exposed
77	T	4.248±0.434 (1.0)**	3.735±0.424 (1.0)**	<i>pK<sup>1</sup></i>	8	36.6 NA
Type III α neurotoxins						
23	T	5.542±0.211 (1.0)**	5.519±0.166 (1.0)**	Esm	6	51.1 Exposed
26	K	5.539±0.237 (0.999)**	5.518±0.178 (1.0)**	Esm	6	49.5 Exposed

Site		CodeML		TreeSAAP		ASA
27	G	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	Esm	6	61.9 Exposed
28	Y	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	Esm	6	88.6 Exposed
29	H	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	Esm	6	52.7 Exposed
30	D	5.536±0.262 (1.0)**	5.517±0.195 (0.999)**	Esm	6	—
35	K	5.542±0.211 (1.0)**	5.519±0.167 (0.999)**	Esm	6	53.4 Exposed
36	P	5.541±0.224 (1.0)**	5.518±0.173 (1.0)**	—	—	99.7 Exposed
37	H	5.270±1.084 (0.941)	5.394±0.757 (0.973)*	—	—	75.4 Exposed
43	E	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	—	—	28.8 NA
45	F	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	—	—	22.8 NA
46	I	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	—	—	58.7 Exposed
47	P	5.540±0.232 (0.999)**	5.518±0.177 (0.999)**	—	—	96.4 Exposed
48	A	5.542±0.209 (1.0)**	5.519±0.166 (1.0)**	—	—	73.7 Exposed
49	T	5.542±0.210 (1.0)**	5.519±0.166 (1.0)**	—	—	69.1 Exposed
50	H	5.360±0.904 (0.961)*	5.438±0.620 (0.983)*	—	—	58.1 Exposed
51	G	5.214±1.172 (0.930)	5.393±0.758 (0.973)*	—	—	77.1 Exposed
52	N	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	—	—	90.3 Exposed
53	A	5.536±0.269 (0.999)**	5.516±0.201 (0.999)**	—	—	47.6 Part. Exposed
54	I	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	—	—	11.7 Buried
55	L	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	—	—	35.9 NA
56	A	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	—	—	45.2 Part. Exposed
57	R	5.196±1.205 (0.925)	5.367±0.829 (0.967)**	—	—	16 Buried
60	G	5.542±0.211 (1.0)**	5.519±0.166 (1.0)**	Esm	6	22.8 NA

Site		CodeML		TreeSAAP		ASA
65	G	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	Esm	6	77.9 Exposed
66	G	5.542±0.209 (1.0)**	5.519±0.166 (1.0)**	Esm	6	100 Exposed
67	I	5.539±0.243 (0.999)**	5.518±0.181 (1.0)**	Esm	6	60.4 Exposed
68	R	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	Esm	6	12 Buried
69	P	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	Esm	6	—
79	K	5.542±0.209 (1.0)**	5.519±0.165 (1.0)**	—	—	—
Plesiotypic $\alpha$ -neurotoxins from 'non-front-fanged' advanced snakes						
21	H	3.082±0.722 (0.926)	2.484±0.206 (0.986)*	—	—	38.5 NA
22	G	3.259±0.429 (1.0)**	2.507±0.086 (1.0)**	—	—	13.4 Buried
23	F	3.246±0.460 (0.994)**	2.505±0.106 (0.998)**	—	—	46.3 Part. Exposed
25	L	3.255±0.438 (0.998)**	2.506±0.092 (0.999)**	—	—	0.4 Buried
29	—	3.039±0.773 (0.907)	2.462±0.278 (0.973)*	—	—	—
30	R	3.258±0.431 (0.999)**	2.507±0.089 (1.0)**	—	—	31.7 NA
32	T	3.161±0.619 (0.958)*	2.486±0.203 (0.987)*	—	—	58.3 Exposed
33	W	3.206±0.542 (0.977)*	2.493±0.172 (0.991)**	—	—	99 Exposed
34	S	3.258±0.431 (0.999)**	2.507±0.090 (1.0)**	—	—	52.8 Exposed
37	S	3.259±0.428 (1.0)**	2.507±0.084 (1.0)**	—	—	92.7 Exposed
38	I	3.259±0.428 (1.0)**	2.507±0.085 (1.0)**	—	—	46.6 Part. Exposed
39	G	3.257±0.433 (0.999)**	2.507±0.089 (1.0)**	—	—	9.2 Buried
40	H	3.258±0.430 (0.999)**	2.507±0.087 (1.0)**	—	—	60.6 Exposed
41	R	2.998±0.810 (0.891)	2.477±0.229 (0.982)*	—	—	82.2 Exposed
43	L	3.259±0.429 (1.0)**	2.507±0.086 (1.0)**	—	—	82.7 Exposed
44	P	3.126±0.664 (0.945)	2.492±0.175 (0.991)**	—	—	50.8 Exposed

Site		CodeML		TreeSAAP		ASA
46	H	3.032±0.776 (0.906)	2.482±0.214 (0.984)*	—	—	26.2 NA
47	M	3.259±0.429 (1.0)**	2.507±0.086 (1.0)**	—	—	52.7 Exposed
48	T	3.187±0.574 (0.970)*	2.496±0.158 (0.993)**	—	—	22.5 NA
53	Y	3.149±0.634 (0.954)*	2.491±0.179 (0.990)**	—	—	31.6 NA
54	K	3.190±0.568 (0.971)*	2.499±0.142 (0.995)**	—	—	41.3 Part. Exposed
55	P	<b>3.258±0.432</b> <b>(0.999)**</b>	<b>2.507±0.088</b> <b>(1.0)**</b>	<i>V<sup>o</sup></i>	<b>6</b>	40.9 <b>Part. Exposed</b>
56	D	<b>3.197±0.556</b> <b>(0.974)*</b>	<b>2.500±0.136</b> <b>(0.995)**</b>	<i>V<sup>o</sup></i>	<b>6</b>	46.2 <b>Part. Exposed</b>
57	E	<b>2.879±0.907</b> <b>(0.843)</b>	<b>2.473±0.241</b> (0.979)*	<i>V<sup>o</sup></i>	<b>6</b>	88.3 <b>Exposed</b>
58	N	<b>3.215±0.524</b> <b>(0.981)*</b>	<b>2.499±0.140</b> (0.995)**	<i>V<sup>o</sup></i>	<b>6</b>	86.5 <b>Exposed</b>
64	A	<b>3.241±0.471</b> <b>(0.992)**</b>	<b>2.504±0.110</b> (0.998)**	<i>V<sup>o</sup></i>	<b>6</b>	32.4 NA
70	R	3.259±0.429 (1.0)**	2.507±0.086 (1.0)**	—	—	52.2 Exposed
71	M	3.073±0.732 (0.922)	2.485±0.203 (0.986)*	—	—	90.6 Exposed
74	T	<b>3.217±0.521</b> <b>(0.982)*</b>	<b>2.501±0.130</b> (0.996)**	<i>V<sup>o</sup></i>	<b>6</b>	100 <b>Exposed</b>
76	K	<b>3.258±0.432</b> <b>(0.999)**</b>	<b>2.507±0.089</b> <b>(1.0)**</b>	<i>V<sup>o</sup></i>	<b>6</b>	82 <b>Exposed</b>
77	S	<b>3.084±0.720</b> <b>(0.927)</b>	<b>2.483±0.210</b> (0.985)*	<i>V<sup>o</sup></i>	<b>6</b>	100 <b>Exposed</b>
80	R	<b>2.457±1.092</b> <b>(0.670)</b>	<b>2.426±0.353</b> (0.951)*	<i>V<sup>o</sup></i>	<b>6</b>	64.8 <b>Exposed</b>
85	T	<b>3.256±0.437</b> <b>(0.998)**</b>	<b>2.506±0.092</b> (0.999)**	<i>V<sup>o</sup></i>	<b>6</b>	83.4 <b>Exposed</b>
86	G	<b>3.257±0.434</b> <b>(0.999)**</b>	<b>2.506±0.091</b> <b>(1.0)**</b>	<i>V<sup>o</sup></i>	<b>6</b>	49.7 <b>Exposed</b>
88	S	3.131±0.658 (0.947)	2.493±0.171 (0.991)**	—	—	34.8 NA
91	S	3.259±0.428 (1.0)**	2.507±0.085 (1.0)**	—	—	64.7 Exposed
92	D	2.905±0.896 (0.850)	2.432±0.351 (0.954)**	—	—	34.9 NA
<b>Plesiotypic <math>\alpha</math>-neurotoxins from Elapidae</b>						
7	S	3.499±0.841 (0.919)	3.474±0.525 (0.969)*	—	—	—

Site		CodeML		TreeSAAP		ASA
28	S	3.485±0.864 (0.913)	3.451±0.581 (0.961)*	—	—	77.6 Exposed
30	Y	3.692±0.532 (0.986)*	3.549±0.296 (0.996)**	—	—	63.0 Exposed
33	P	3.731±0.433 (0.999)**	3.56±0.245 (1.0)**	—	—	66.5 Exposed
34	N	3.694±0.529 (0.986)*	3.549±0.297 (0.996)**	—	—	87.7 Exposed
35	S	3.597±0.707 (0.953)*	3.518±0.407 (0.985)*	—	—	85.8 Exposed
39	P	3.69±0.54 (0.985)*	3.545±0.314 (0.994)**	—	—	85.3 Exposed
40	D	3.724±0.455 (0.996)**	3.558±0.255 (0.999)**	—	—	66.1 Exposed
44	I	3.718±0.47 (0.994)**	3.556±0.264 (0.998)**	—	—	14.8 Buried
48	R	3.68±0.561 (0.981)*	3.543±0.32 (0.994)**	—	—	57.5 Exposed
50	W	3.549±0.776 (0.937)	3.498±0.461 (0.978)*	—	—	41.3 Par. exposed
52	T	3.729±0.44 (0.998)**	3.559±0.248 (1.0)**	—	—	65.8 Exposed
53	A	3.724±0.453 (0.997)**	3.558±0.254 (0.999)**	—	—	91.8 Exposed
54	V	3.733±0.426 (1.0)**	3.56±0.242 (1.0)**	—	—	96.8 Exposed
55	R	3.712±0.486 (0.992)**	3.553±0.276 (0.998)**	—	—	100.0 Exposed
57	R	3.721±0.463 (0.995)**	3.557±0.259 (0.999)**	—	—	42.2 Par. exposed
58	E	3.695±0.526 (0.986)*	3.549±0.294 (0.996)**	—	—	87.0 Exposed
59	I	3.399±0.948 (0.885)	3.43±0.616 (0.954)*	—	—	9.3 Buried
60	R	3.733±0.427 (1.0)**	3.56±0.242 (1.0)**	—	—	91.7 Exposed
69	P	3.708±0.495 (0.991)**	3.553±0.277 (0.997)**	—	—	91.7 Exposed
70	S	3.715±0.477 (0.993)**	3.555±0.27 (0.998)**	—	—	11.8 Buried
72	L	3.712±0.486 (0.992)**	3.554±0.275 (0.998)**	—	—	88.4 Exposed
73	G	3.65±0.622 (0.971)*	3.533±0.358 (0.990)**	—	—	54.0 Exposed



Site		CodeML		TreeSAAP		ASA
74	L	3.687±0.543 (0.984)*	3.546±0.306 (0.995)**	—	—	25.2 NA
75	T	3.722±0.459 (0.996)**	3.557±0.258 (0.999)**	—	—	39.8 Par. exposed
77	F	3.725±0.451 (0.997)**	3.558±0.254 (0.999)**	—	—	42.7 Par. exposed
83	N	3.602±0.697 (0.955)*	3.523±0.389 (0.987)*	—	—	69.0 Exposed
86	H	3.733±0.428 (1.0)**	3.56±0.243 (1.0)**	—	—	100.0 Exposed

**Viperidae 3FTxs**

7	I	6.037±0.994 (0.983)*	5.932±0.85 (0.991)**	—	—	—
18	S	<b>5.874±1.314</b> <b>(0.953)*</b>	<b>5.825±1.11</b> <b>(0.971)*</b>	<i>El, αc</i>	<b>7, 6</b>	—
23	E	<b>5.796±1.430</b> <b>(0.939)</b>	<b>5.784±1.186</b> <b>(0.963)*</b>	<i>El, αc</i>	<b>7, 6</b>	—
25	Y	<b>6.123±0.76</b> <b>(0.999)**</b>	<b>5.979±0.705</b> <b>(1.0)**</b>	<i>El, αc</i>	<b>7, 6</b>	—
28	N	<b>5.995±1.086</b> <b>(0.975)*</b>	<b>5.908±0.914</b> <b>(0.986)*</b>	<i>El, Pr</i>	<b>7, 8</b>	—
29	M	<b>6.128±0.744</b> <b>(1.0)**</b>	<b>5.981±0.697</b> <b>(1.0)**</b>	<i>El, Pr</i>	<b>7, 8</b>	—
30	T	<b>6.128±0.745</b> <b>(1.0)**</b>	<b>5.981±0.698</b> <b>(1.0)**</b>	<i>El, Pr</i>	<b>7, 8</b>	—
31	F	<b>6.12±0.77</b> <b>(0.998)**</b>	<b>5.977±0.71</b> <b>(0.999)**</b>	<i>El, Pr</i>	<b>6, 8</b>	—
34	L	<b>6.128±0.745</b> <b>(1.0)**</b>	<b>5.981±0.698</b> <b>(1.0)**</b>	<i>El, Pr</i>	<b>6, 8</b>	—
36	R	<b>6.122±0.766</b> <b>(0.999)**</b>	<b>5.978±0.709</b> <b>(0.999)**</b>	<i>El, Pr</i>	<b>6, 8</b>	—
40	E	<b>6.004±1.065</b> <b>(0.977)*</b>	<b>5.913±0.9</b> <b>(0.987)*</b>	<i>El, Pr</i>	<b>8, 7</b>	<b>100</b> <b>Exposed</b>
42	L	<b>6.07±0.913</b> <b>(0.989)*</b>	<b>5.952±0.792</b> <b>(0.995)**</b>	<i>El, Pr</i>	<b>8</b>	<b>32.0</b> <b>NA</b>
49	K	<b>6.042±0.984</b> <b>(0.984)*</b>	<b>5.934±0.844</b> <b>(0.991)**</b>	<i>El</i>	<b>8</b>	<b>48.8</b> <b>Par. Exposed</b>
51	—	<b>6.126±0.753</b> <b>(0.999)**</b>	<b>5.98±0.702</b> <b>(1.0)**</b>	<i>El</i>	<b>8</b>	<b>100</b> <b>Exposed</b>
54	L	5.757±1.510 (0.932)	5.716±1.325 (0.951)*	—	—	—
55	F	6.106±0.815 (0.996)**	5.969±0.738 (0.998)**	—	—	16.1 Buried
56	P	6.037±0.995 (0.983)*	5.932±0.851 (0.991)**	—	—	100 Exposed

Site		CodeML		TreeSAAP		ASA
57	V	5.757±1.485 (0.932)	5.754±1.241 (0.958)*	—	—	91.3 Exposed
58	L	5.965±1.156 (0.969)*	5.878±0.996 (0.980)*	—	—	42.9 Par. Exposed
59	K	5.818±1.400 (0.943)	5.795±1.166 (0.965)*	—	—	64.2 Exposed
61	E	5.780±1.449 (0.936)	5.775±1.199 (0.962)*	—	—	55.2 Exposed
70	Q	<b>5.939±1.205</b> <b>(0.965)*</b>	<b>5.863±1.029</b> <b>(0.978)*</b>	<i>Pr</i>	7	<b>100.0</b> <b>Exposed</b>
72	W	<b>6.127±0.75</b> <b>(1.0)**</b>	<b>5.98±0.7</b> <b>(1.0)**</b>	<i>Pr, αc</i>	7, 6	<b>98.5</b> <b>Exposed</b>
73	T	<b>6.119±0.775</b> <b>(0.998)**</b>	<b>5.977±0.712</b> <b>(0.999)**</b>	<i>Pr, αc</i>	7, 6	<b>43.5</b> <b>Par. Exposed</b>
74	D	<b>6.069±0.913</b> <b>(0.989)*</b>	<b>5.953±0.788</b> <b>(0.995)**</b>	<i>Pr, αc</i>	7, 6	<b>2.8</b> <b>Buried</b>
75	K	<b>5.802±1.430</b> <b>(0.940)</b>	<b>5.773±1.212</b> <b>(0.961)*</b>	<i>El, Pr, αc</i>	8, 7, 6	<b>92.4</b> <b>Exposed</b>
78	E	<b>6.109±0.804</b> <b>(0.996)**</b>	<b>5.972±0.728</b> <b>(0.998)**</b>	<i>El, Pr, αc</i>	8, 7, 6	<b>70.8</b> <b>Exposed</b>
80	N	<b>5.885±1.287</b> <b>(0.955)*</b>	<b>5.848±1.053</b> <b>0.975*</b>	<i>El, αc</i>	8, 6	<b>98.7</b> <b>Exposed</b>
81	K	<b>6.112±0.795</b> <b>(0.997)**</b>	<b>5.973±0.724</b> <b>(0.999)**</b>	<i>El, αc</i>	8, 6	<b>83.2</b> <b>Exposed</b>
84	I	6.127±0.747 (1.0)**	5.981±0.698 (1.0)**	—	—	—
κ-bungarotoxins						
37	Q	8.983±1.705 0.982*	8.708±1.708 (0.989)*	—	—	49.1 Par. Exposed
44	L	9.069±1.500 0.993**	8.761±1.593 (0.995)**	—	—	40 Par. Exposed
47	Q	9.121±1.355 (0.999)**	8.792±1.515 (0.999)**	—	—	57.6 Exposed
50	K	8.956±1.761 0.979*	8.692±1.74 (0.987)*	—	—	39.8 Par. Exposed
53	S	9.126±1.341 (1.0)**	8.795±1.507 (1.0)**	—	—	62.7 Exposed
Cytotoxins						
50	T	7.473±1.990 (0.996)**	6.602±2.042 (0.999)**	<i>Pα, K<sup>0</sup></i>	6, 7	75.2 Exposed
51	P	7.435±2.057 (0.988)*	6.590±2.062 (0.996)**	<i>Pα, K<sup>0</sup></i>	6, 7	45.7 Part. exposed

**Amino-acid property symbols used:**  $\alpha$ -helical tendencies ( $P\alpha$ ), Compressibility ( $K^0$ ), Equilibrium constant (ionization of COOH) ( $pK^I$ ), Hydropathy ( $h$ ), Long-range n.b. energy ( $El$ ), Normalized consensus hydrophobicity ( $Hnc$ ), Partial specific volume ( $V^0$ ), Polar requirement ( $Pr$ ), Power to be at C-terminus of  $\alpha$ -helix ( $\alpha c$ ), Short and medium-range n.b. energy ( $Esm$ ), Solvent accessible reduction ratio ( $R\alpha$ ) and Surrounding hydrophobicity ( $Hp$ ).

**Legend:**

**a:** M2a Bayes Empirical Bayes (BEB) posterior probability (\*  $\geq 0.95$ ; \*\*  $\geq 0.99$ ) and post-mean omega indicated in brackets

**b:** M8 Bayes Empirical Bayes (BEB) posterior probability (\*  $\geq 0.95$ ; \*\*  $\geq 0.99$ ) and post-mean omega indicated in brackets

**c:** amino acid property under selection

**d:** magnitude of selection on the amino acid property

**ASA:** Accessible surface area (50%  $\geq$  Side chains completely exposed; 20%  $\leq$  Side chains buried)

**Part. exposed:** Partially exposed side-chains (ASA: 40%-50%)

Sites detected as positively selected by both nucleotide and amino acid-level analyses are indicated in bold.

**Supplementary Table 12. Surface accessibility of Three-finger toxins**

**Type I  $\alpha$ -neurotoxin**

<b>Total Residues</b>	62
<b>Total Exposed</b>	33
<b>Total Buried</b>	10
<b>Exposed PS</b>	15 (24%)
<b>Buried PS</b>	2 (3%)
<b>Frequency of exposed PS sites (a)</b>	45%
<b>Frequency of buried PS sites (b)</b>	20%
<b>Exposure Ratio (a/b)</b>	2.3%

**Type II  $\alpha$ -neurotoxin**

<b>Total Residues</b>	74
<b>Total Exposed</b>	29
<b>Total Buried</b>	20
<b>Exposed PS</b>	14 (19%)
<b>Buried PS</b>	3 (4%)
<b>Frequency of exposed PS sites (a)</b>	48%
<b>Frequency of buried PS sites (b)</b>	15%
<b>Exposure Ratio (a/b)</b>	3.2%

**Type III  $\alpha$ -neurotoxin**

<b>Total Residues</b>	57
<b>Total Exposed</b>	28
<b>Total Buried</b>	14
<b>Exposed PS</b>	20 (35%)
<b>Buried PS</b>	3 (5%)
<b>Frequency of exposed PS sites (a)</b>	71%
<b>Frequency of buried PS sites (b)</b>	21%
<b>Exposure Ratio (a/b)</b>	3.3%

**'Non-front-fanged' Advanced Snakes**

<b>Total Residues</b>	74
<b>Total Exposed</b>	32
<b>Total Buried</b>	17
<b>Exposed PS</b>	25 (34%)
<b>Buried PS</b>	3 (4%)
<b>Frequency of exposed PS sites (a)</b>	78%
<b>Frequency of buried PS sites (b)</b>	18%
<b>Exposure Ratio (a/b)</b>	4.4%

**Viperidae**

<b>Total Residues</b>	46
<b>Total Exposed</b>	23
<b>Total Buried</b>	8
<b>Exposed PS</b>	15 (33%)
<b>Buried PS</b>	2 (4%)
<b>Frequency of exposed PS sites (a)</b>	65%
<b>Frequency of buried PS sites (b)</b>	25%
<b>Exposure Ratio (a/b)</b>	2.6%

**Elapidae**

<b>Total Residues</b>	65
<b>Total Exposed</b>	32
<b>Total Buried</b>	14
<b>Exposed PS</b>	23 (35%)
<b>Buried PS</b>	3 (5%)
<b>Frequency of exposed PS sites (a)</b>	72%
<b>Frequency of buried PS sites (b)</b>	21%
<b>Exposure Ratio (a/b)</b>	3.4%

**κ-neurotoxins**

<b>Total Residues</b>	132
<b>Total Exposed</b>	47
<b>Total Buried</b>	42
<b>Exposed PS</b>	3 (2%)
<b>Buried PS</b>	0
<b>Frequency of exposed PS sites (a)</b>	6%
<b>Frequency of buried PS sites (b)</b>	0
<b>Exposure Ratio (a/b)</b>	—

**Cytotoxins**

<b>Total Residues</b>	60
<b>Total Exposed</b>	28
<b>Total Buried</b>	15
<b>Exposed PS</b>	2 (3%)
<b>Buried PS</b>	0
<b>Frequency of exposed PS sites (a)</b>	7%
<b>Frequency of buried PS sites (b)</b>	0
<b>Exposure Ratio (a/b)</b>	—

**Legend:** PS: Positively selected

**Note:**

- Type I α-neurotoxins had 39.4% of the exposed residues and 20% of the buried residues under positive selection. Thus, the exposed residues being **1.9 times** more likely to be positively selected than buried residues.
- Type II α-neurotoxins had 36.8% of the exposed residues and 15% of the buried residues under positive selection. Thus, the exposed residues being **2.5 times** more likely to be positively selected than buried residues.
- Type III α-neurotoxin had 58.8% of the exposed residues and 21.4% of the buried residues under positive selection. Thus, the exposed residues being **2.7 times** more likely to be positively selected than buried residues.
- The plesiotypic ‘non-front-fanged’ advanced snake 3FTx had 62.5% of the exposed residues and 17.6% of the buried residues under positive selection. Thus, the exposed residues being **3.5 times** more likely to be positively selected than buried residues.
- The plesiotypic Viperidae 3FTx had 51.7% of the exposed residues and 25% of the buried residues under positive selection. Thus, the exposed residues being **2.1 times** more likely to be positively selected than buried residues.
- The plesiotypic Elapidae 3FTx had 58.9% of the exposed residues positively selected while 21.4% of the buried residues under positive selection. Thus, the exposed residues being **2.8 times** more likely to be positively selected than buried residues.
- κ-neurotoxins had 5% of the exposed residues under positive selection, while none of the buried residues were positively selected.
- Cytotoxic 3FTx had 5.8% of the exposed residues under positive selection, while none of the buried residues were positively selected.

**Supplementary Table 13. Structural and functional residues in 3FTx**

3FTx	Structurally and/or functionally important residue	Reference
<b>α-neurotoxins</b>		
<b>Type I (short-chain)</b>	Q6 (87%), S8 (95%), S9 (95%), Q10 (87%), Y25 (invariant), K27 (94%), W29 (95%), D31 (91%), R33 (89%), G34 (94%), E38 (99%), G40 (invariant), P44 (99%), K47 (93%)	(Pillet et al. 1993; Treméau et al. 1995; Antil et al. 1999; Barber et al. 2013)
<b>Type II (long-chain)</b>	Y21 (72%), K23 (84%), W25 (98%), C26 (94%), D27 (91%), A28 (50%; PS), F29 (49%; PS), C30 (94%), R33 (83%), K35 (73%), R36 (very low; PS), G40 (invariant), P46 (98%), K49 (70%), F65 (very low; PS)	(Antil et al. 1999; Antil-Delbeke et al. 2000; Barber et al. 2013)
<b>Type III</b>	L1 (invariant), T20 (98%), S43 (90%), V51 (91%), S54 (91%), T55 (93%), D56 (invariant), N59 (invariant)	Predicted in this study as putative functional/structural residue
<b>Plesiotypic ‘non-front-fanged’ advanced snakes</b>	E64 (95%), N75 (95%)	Predicted in this study as putative functional/structural residue
<b>Plesiotypic Elapidae 3FTx</b>	K28 (invariant), R42 (invariant), P49 (invariant), V57 (96%), T62 (93%), D63 (invariant), N66 (96%)	Predicted in this study as putative functional/structural residue
<b>Viperidae 3FTx</b>	P20 (90%), G45 (invariant), K59 (90%), T66 (90%), N70 (invariant)	Predicted in this study as putative functional/structural residue
<b>κ-bungarotoxin</b>	R32 (invariant), P45 (invariant), F47 (invariant), L55 (invariant)	(Dewan et al. 1994)
<b>Cytotoxin</b>	K5 (83%), Y11 (72%), K12 (invariant), K18 (97%), Y22 (invariant), K23 (invariant), M24 (94%), M26 (invariant), K31 (56%), K35 (invariant), G37 (invariant), P43 (invariant), K44 (invariant), K50 (invariant), Y51 (invariant)	(Kumar et al. 1997)

**PS:** Positively selected.

**Percent identity:** has been indicated in parenthesis for each site.

**Very low:** very few sequences have the structurally/functionally important residue at this site.

**Note:** All site numbering corresponds to H8PG58 for short-chain, FJ752458.1 for long-chain, AF082975.1 for Type III, DQ366293.1 for basal 3FTx from ‘non-front-fanged’ advanced snakes, AY611643.1 for basal 3FTx from Elapidae, AY057872.1 for kappa and U42585.1 for cytotoxins.

## References

- Antil S, Servent D, Menez A. 1999. Variability among the sites by which curaremimetic toxins bind to torpedo acetylcholine receptor, as revealed by identification of the functional residues of alpha-cobratoxin. *J Biol Chem* 274:34851–34858.
- Antil-Delbeke S, Gaillard C, Tamiya T, Corringer PJ, Changeux JP, Servent D, Menez a. 2000. Molecular determinants by which a long chain toxin from snake venom interacts with the neuronal alpha 7-nicotinic acetylcholine receptor. *The Journal of biological chemistry* 275:29594–29601.
- Barber CM, Isbister GK, Hodgson WC. 2013. Alpha neurotoxins. *Toxicon : official journal of the International Society on Toxinology* 66C:47–58.
- Dewan JC, Grant GA, Sacchettini JC. 1994. Crystal structure of kappa-bungarotoxin at 2.3-Å resolution. *Biochemistry* 33:13147–13154.
- Kumar TK, Jayaraman G, Lee CS, Arunkumar AI, Sivaraman T, Samuel D, Yu C. 1997. Snake venom cardiotoxins-structure, dynamics, function and folding. *Journal of biomolecular structure dynamics* 15:431–463.
- Pillet L, Tremeau O, Ducancel F, Drevet P, Zinn-Justin S, Pinkasfeld S, Boulain JC, Menez A. 1993. Genetic engineering of snake toxins. Role of invariant residues in the structural and functional properties of a curaremimetic toxin, as probed by site-directed mutagenesis. *J Biol Chem* 268:909–916.
- Tremeau O, Lemaire C, Drevet P, Pinkasfeld S, Ducancel F, Boulain JC, Menez A. 1995. Genetic engineering of snake toxins. The functional site of Erabutoxin a, as delineated by site-directed mutagenesis, includes variant residues. *J Biol Chem* 270:9362–9369.